NASDAQ:LRMR

Larimar Therapeutics Competitors

$14.23
-0.56 (-3.79 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.19
Now: $14.23
$15.09
50-Day Range
$14.61
MA: $16.97
$19.00
52-Week Range
$8.64
Now: $14.23
$25.87
Volume26,708 shs
Average Volume64,827 shs
Market Capitalization$218.69 million
P/E RatioN/A
Dividend YieldN/A
Beta0.65

Competitors

Larimar Therapeutics (NASDAQ:LRMR) Vs. DYN, AFMD, EPZM, AMPH, COLL, and ORIC

Should you be buying LRMR stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Larimar Therapeutics, including Dyne Therapeutics (DYN), Affimed (AFMD), Epizyme (EPZM), Amphastar Pharmaceuticals (AMPH), Collegium Pharmaceutical (COLL), and ORIC Pharmaceuticals (ORIC).

Larimar Therapeutics (NASDAQ:LRMR) and Dyne Therapeutics (NASDAQ:DYN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.

Insider & Institutional Ownership

88.8% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 59.4% of Dyne Therapeutics shares are owned by institutional investors. 5.1% of Larimar Therapeutics shares are owned by insiders. Comparatively, 1.8% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Larimar Therapeutics and Dyne Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Larimar TherapeuticsN/A-38.70%-31.40%
Dyne TherapeuticsN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and price targets for Larimar Therapeutics and Dyne Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Larimar Therapeutics00203.00
Dyne Therapeutics00503.00

Larimar Therapeutics presently has a consensus target price of $29.00, indicating a potential upside of 103.79%. Dyne Therapeutics has a consensus target price of $34.25, indicating a potential upside of 104.48%. Given Dyne Therapeutics' higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than Larimar Therapeutics.

Earnings and Valuation

This table compares Larimar Therapeutics and Dyne Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Larimar TherapeuticsN/AN/A$-45,410,000.00N/AN/A
Dyne TherapeuticsN/AN/AN/AN/AN/A

Summary

Dyne Therapeutics beats Larimar Therapeutics on 4 of the 6 factors compared between the two stocks.

Larimar Therapeutics (NASDAQ:LRMR) and Affimed (NASDAQ:AFMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.

Volatility & Risk

Larimar Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Affimed has a beta of 2.81, meaning that its stock price is 181% more volatile than the S&P 500.

Insider & Institutional Ownership

88.8% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 52.3% of Affimed shares are owned by institutional investors. 5.1% of Larimar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Larimar Therapeutics and Affimed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Larimar TherapeuticsN/A-38.70%-31.40%
Affimed-172.01%-99.24%-37.40%

Analyst Ratings

This is a breakdown of current ratings and price targets for Larimar Therapeutics and Affimed, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Larimar Therapeutics00203.00
Affimed00403.00

Larimar Therapeutics presently has a consensus target price of $29.00, indicating a potential upside of 103.79%. Affimed has a consensus target price of $13.50, indicating a potential upside of 38.60%. Given Larimar Therapeutics' higher probable upside, equities analysts clearly believe Larimar Therapeutics is more favorable than Affimed.

Earnings and Valuation

This table compares Larimar Therapeutics and Affimed's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Larimar TherapeuticsN/AN/A$-45,410,000.00N/AN/A
Affimed$23.96 million35.91$-36,250,000.00($0.56)-17.39

Affimed has higher revenue and earnings than Larimar Therapeutics.

Summary

Larimar Therapeutics beats Affimed on 7 of the 11 factors compared between the two stocks.

Larimar Therapeutics (NASDAQ:LRMR) and Epizyme (NASDAQ:EPZM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.

Volatility & Risk

Larimar Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Epizyme has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500.

Earnings and Valuation

This table compares Larimar Therapeutics and Epizyme's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Larimar TherapeuticsN/AN/A$-45,410,000.00N/AN/A
Epizyme$23.80 million35.80$-170,290,000.00($1.93)-4.34

Larimar Therapeutics has higher earnings, but lower revenue than Epizyme.

Insider & Institutional Ownership

88.8% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 89.8% of Epizyme shares are owned by institutional investors. 5.1% of Larimar Therapeutics shares are owned by insiders. Comparatively, 16.3% of Epizyme shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Larimar Therapeutics and Epizyme's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Larimar TherapeuticsN/A-38.70%-31.40%
Epizyme-1,899.35%-83.45%-52.66%

Analyst Ratings

This is a breakdown of current ratings and price targets for Larimar Therapeutics and Epizyme, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Larimar Therapeutics00203.00
Epizyme04302.43

Larimar Therapeutics presently has a consensus target price of $29.00, indicating a potential upside of 103.79%. Epizyme has a consensus target price of $17.00, indicating a potential upside of 103.11%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Larimar Therapeutics is more favorable than Epizyme.

Summary

Larimar Therapeutics beats Epizyme on 7 of the 12 factors compared between the two stocks.

Larimar Therapeutics (NASDAQ:LRMR) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.

Risk and Volatility

Larimar Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Valuation and Earnings

This table compares Larimar Therapeutics and Amphastar Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Larimar TherapeuticsN/AN/A$-45,410,000.00N/AN/A
Amphastar Pharmaceuticals$322.36 million2.63$48.94 million$0.3649.69

Amphastar Pharmaceuticals has higher revenue and earnings than Larimar Therapeutics.

Insider and Institutional Ownership

88.8% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 55.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 5.1% of Larimar Therapeutics shares are owned by company insiders. Comparatively, 29.8% of Amphastar Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Larimar Therapeutics and Amphastar Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Larimar TherapeuticsN/A-38.70%-31.40%
Amphastar Pharmaceuticals1.97%5.50%4.04%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Larimar Therapeutics and Amphastar Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Larimar Therapeutics00203.00
Amphastar Pharmaceuticals03102.25

Larimar Therapeutics currently has a consensus target price of $29.00, indicating a potential upside of 103.79%. Amphastar Pharmaceuticals has a consensus target price of $21.6667, indicating a potential upside of 21.11%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Larimar Therapeutics is more favorable than Amphastar Pharmaceuticals.

Summary

Amphastar Pharmaceuticals beats Larimar Therapeutics on 8 of the 12 factors compared between the two stocks.

Larimar Therapeutics (NASDAQ:LRMR) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.

Risk and Volatility

Larimar Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.

Valuation and Earnings

This table compares Larimar Therapeutics and Collegium Pharmaceutical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Larimar TherapeuticsN/AN/A$-45,410,000.00N/AN/A
Collegium Pharmaceutical$296.70 million2.73$-22,720,000.00($0.68)-34.31

Collegium Pharmaceutical has higher revenue and earnings than Larimar Therapeutics.

Insider and Institutional Ownership

88.8% of Larimar Therapeutics shares are owned by institutional investors. 5.1% of Larimar Therapeutics shares are owned by company insiders. Comparatively, 8.1% of Collegium Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Larimar Therapeutics and Collegium Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Larimar TherapeuticsN/A-38.70%-31.40%
Collegium Pharmaceutical5.71%12.64%3.15%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Larimar Therapeutics and Collegium Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Larimar Therapeutics00203.00
Collegium Pharmaceutical11202.25

Larimar Therapeutics currently has a consensus target price of $29.00, indicating a potential upside of 103.79%. Collegium Pharmaceutical has a consensus target price of $25.00, indicating a potential upside of 7.16%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Larimar Therapeutics is more favorable than Collegium Pharmaceutical.

Summary

Collegium Pharmaceutical beats Larimar Therapeutics on 8 of the 11 factors compared between the two stocks.

Larimar Therapeutics (NASDAQ:LRMR) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.

Insider and Institutional Ownership

88.8% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 73.4% of ORIC Pharmaceuticals shares are owned by institutional investors. 5.1% of Larimar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Larimar Therapeutics and ORIC Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Larimar Therapeutics00203.00
ORIC Pharmaceuticals01602.86

Larimar Therapeutics currently has a consensus target price of $29.00, indicating a potential upside of 103.79%. ORIC Pharmaceuticals has a consensus target price of $43.7143, indicating a potential upside of 102.66%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Larimar Therapeutics is more favorable than ORIC Pharmaceuticals.

Valuation and Earnings

This table compares Larimar Therapeutics and ORIC Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Larimar TherapeuticsN/AN/A$-45,410,000.00N/AN/A
ORIC PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares Larimar Therapeutics and ORIC Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Larimar TherapeuticsN/A-38.70%-31.40%
ORIC PharmaceuticalsN/AN/AN/A

Summary

Larimar Therapeutics beats ORIC Pharmaceuticals on 4 of the 7 factors compared between the two stocks.


Larimar Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$16.75-0.0%$861.92 millionN/A0.00
Affimed logo
AFMD
Affimed
1.6$9.74-19.0%$860.30 million$23.96 million-16.51High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Gap Down
Epizyme logo
EPZM
Epizyme
1.8$8.37-0.6%$851.94 million$23.80 million-3.75
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.5$17.89-0.6%$848.58 million$322.36 million127.79
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$23.33-1.3%$810.86 million$296.70 million47.61
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.57-7.5%$791.51 millionN/A0.00Gap Down
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.37-1.1%$775.18 million$322.07 million-5.11
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.4$26.95-4.7%$753.06 million$148.36 million-7.00News Coverage
Gap Down
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$10.02-1.2%$747.83 million$40.89 million-3.46
Veru logo
VERU
Veru
1.4$10.35-0.3%$744.29 million$42.59 million-36.96
Ardelyx logo
ARDX
Ardelyx
1.6$7.44-5.6%$734.18 million$5.28 million-7.37Gap Down
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$22.17-5.3%$731.97 million$252 million-2.27Gap Down
Chimerix logo
CMRX
Chimerix
1.3$8.45-2.1%$723.99 million$12.52 million-14.82News Coverage
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.82-1.8%$716.29 million$2.22 million-16.59
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.32-2.1%$714.48 million$150,000.00-4.74Gap Down
OrganiGram logo
OGI
OrganiGram
1.6$3.05-3.3%$708.43 million$64.61 million-4.49Upcoming Earnings
Analyst Upgrade
Gap Down
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$27.50-0.0%$686.58 million$19.56 million-19.78High Trading Volume
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.74-3.3%$660.12 millionN/A-2.46Gap Down
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$28.38-13.7%$655.29 million$13.80 million-13.71Insider Selling
High Trading Volume
News Coverage
Gap Down
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.23-5.6%$651.22 million$143.01 million-1.19Gap Down
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$19.86-9.5%$640.68 millionN/A-10.56Gap Down
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$26.15-0.1%$635.65 million$12.69 million-12.57
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$17.62-1.3%$630.96 million$6.83 million-18.16News Coverage
Kadmon logo
KDMN
Kadmon
1.8$3.66-5.2%$628.85 million$5.09 million-6.10Analyst Upgrade
Gap Down
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$32.88-2.4%$628.47 million$9.64 million-5.36
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$14.82-3.0%$624.78 million$17.26 million-4.12Earnings Announcement
Analyst Revision
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$12.32-9.9%$598.21 millionN/A-6.32Analyst Upgrade
News Coverage
Gap Down
Evolus logo
EOLS
Evolus
1.1$13.58-2.4%$593.89 million$34.92 million-6.69Analyst Report
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$35.23-2.0%$590.00 millionN/A-16.31Gap Down
AnaptysBio logo
ANAB
AnaptysBio
1.5$20.87-6.3%$571.13 million$8 million-7.70Gap Down
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$12.04-4.1%$568.85 millionN/A-9.33Gap Down
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$15.52-3.3%$567.69 millionN/A-4.47News Coverage
Gap Up
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$17.07-4.9%$563.81 million$1.19 million-7.11Insider Buying
News Coverage
Gap Down
Inventiva logo
IVA
Inventiva
0.0$14.44-2.2%$557.76 millionN/A0.00Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.26-1.8%$554.59 million$59.29 million-21.73
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.20-5.2%$553.64 millionN/A-5.29Analyst Upgrade
Gap Down
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.4$41.56-0.9%$549.30 million$195.89 million118.75News Coverage
SIGA
SIGA Technologies
0.3$7.10-0.6%$544.91 million$26.74 million17.75
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$39.66-5.1%$535.77 million$40,000.00-1.72High Trading Volume
Gap Up
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$10.04-0.2%$535.48 millionN/A-4.03
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24-0.0%$531.75 millionN/A-3.15
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.32-0.0%$530.72 million$49.65 million-1.86News Coverage
Gap Down
IVERIC bio logo
ISEE
IVERIC bio
1.5$5.87-4.3%$529.13 millionN/A-4.66Gap Down
89bio logo
ETNB
89bio
1.6$26.28-0.2%$524.18 millionN/A-5.20
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$21.04-5.1%$523.18 millionN/A-8.28News Coverage
Gap Down
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$5.44-10.3%$516.29 million$36.63 million-6.40Analyst Downgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Gap Up
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.78-0.0%$513.32 million$59.22 million43.90News Coverage
Provention Bio logo
PRVB
Provention Bio
1.6$8.00-21.6%$507 millionN/A-5.37Analyst Report
High Trading Volume
Unusual Options Activity
News Coverage
Gap Up
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$11.97-0.9%$506.64 million$25 million-18.42
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$14.00-0.3%$502.28 million$58.12 million-16.28
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.